VILLEJUIF, France--(BUSINESS WIRE)--The organizers of the WIN Symposia, a series of global cross-sector meetings focused on personalized cancer medicine, today proudly announce that ASCO has endorsed the WIN 2013 Symposium. This marks the 5th consecutive year that WIN Symposia have received ASCO’s endorsement, made in recognition of the outstanding scientific quality of the congress.
“We are thrilled that ASCO has again chosen to endorse the WIN Symposium,” said Alexander Eggermont, Director General of the Institut Gustave Roussy and Vice-Chair of the WIN Consortium. “With ASCO’s tremendous global stature and its vision to transform cancer care, this endorsement is important to WIN’s goal of making an impact on personalized cancer therapy around the globe.” ASCO joins ESMO, EORTC, ESO, and UICC in endorsing WIN2013.
WIN2013, focused on the theme of Personalized Cancer Medicine: From Innovation to Implementation, will be held July 10-12, 2013, in Paris, France. WIN Symposia traditionally bring together, from over 30 countries, hundreds of delegates representing all stakeholders in personalized cancer medicine: academia, clinical practice, pharma, biotech, life-sciences, healthcare IT, regulatory, health plan, and patient advocacy. WIN2013, a collaborative global forum designed to foster innovation and collaboration in personalized cancer medicine, will feature a cross-sector lineup of internationally recognized experts presenting in plenary sessions on:
-
OMICS assays that support personalized clinical care today
Moderator: Alexander Eggermont, Institut Gustave Roussy -
Analysis and clinical application of genomics
Moderator: Levi Garraway, Dana-Farber Cancer Institute -
Clinical progress in personalized cancer therapy
Moderator: Richard L. Schilsky, ASCO -
New approaches that impact personalized cancer care
Moderator: John Mendelsohn, MD Anderson Cancer Center
Registration information and the full scientific program are available online: www.winsymposium.org.
WIN Symposia are an initiative of the Worldwide Innovative Networking (WIN) Consortium in personalized cancer medicine. The WIN Consortium (www.winconsortium.org) is a non-profit global collaboration of academic, industry, and advocacy organizations created to accelerate the pace and reduce the cost of translating novel cancer treatments to the bedside.
This program has the American Society of Clinical Oncology’s approval for quality of educational content. ASCO endorsement does not constitute medical advice. Health care providers should exercise their own independent medical judgment. ASCO® is a registered trademark of the American Society of Clinical Oncology®. Used with permission. This is not an ASCO sponsored event.